Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

at the Institut Jules Bordet in Brussels, Belgium.  "The high confirmed objective response rate continues to show that NKTR-102 is one of the most active single agents in this disease.  This is particularly evident given the number of patients with dramatic reduction in lung and liver metastases."

The confirmed ORR was maintained in poor prognosis and heavily pre-treated subsets within the study, including patients previously treated with anthracycline/taxane/capecitabine: 33% (5/15); patients with metastatic triple-negative breast cancer: 39% (7/18); and patients with visceral disease: 29% (17/58).  As of October 26, 2010, preliminary median progression-free survival (PFS) for all patients was 20 weeks. [Efficacy Tables, Figures A - C]

"We are in critical need of effective new therapeutic options whose mechanism of action is different from those already available for women with metastatic breast cancer," continued Dr. Awada.  "This is especially true for those patients whose disease has progressed despite treatment with anthracyclines and taxanes.  NKTR-102 is emerging as an important investigational treatment in metastatic breast cancer and has the potential to be the first topoisomerase 1 inhibitor in this disease.  NKTR-102 should enter Phase 3 clinical studies as quickly as possible."

Patients treated in the single-agent NKTR-102 study had a median of two lines of prior cytotoxic treatments for metastatic disease.  Seventy-three percent (51/70) of the patients received neoadjuvant and/or adjuvant therapy and 87% (61/70) had visceral disease.  

"NKTR-102 is quickly emerging as a very important potential new drug in the fight against cancer," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer.  "The drug has consistently high response rates as a single-agent in multiple Phase 1 and 2 clinical studies to-date, including our study in platinum-resistant ova
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Many new dentists who are opening their own ... their practice will be a success. DentalDisposables.net is here to ... the most can make all the difference. Dentistry is a ... that purchasing discount dental supplies can make the ... successful dentists across the United States ...
(Date:7/24/2014)... , July 24, 2014  Kinex Pharmaceuticals announced the ... the Company,s KX2-391 Ointment for the commencement of a ... the Company,s third IND to be allowed by the ... KX2-391 is a synthetic, orally active and highly selective ... KX2-391 promotes the induction of p53, G2/M arrest of ...
(Date:7/24/2014)... 2014 Research and Markets  has announced ... by Product, Component, Application and Geography - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 ... witness a moderate growth as the markets of the ... reached the saturation levels. The demand is expected to ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
(Date:7/24/2014)... to light at night, which shuts off nighttime production ... to tamoxifen, a widely used breast cancer drug, says ... cancer researchers. The study, "Circadian and Melatonin Disruption by ... Tamoxifen Therapy in Breast Cancer," published in the journal ... that melatonin is vital to the success of tamoxifen ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... may be dead wrong, according to a small study that asked ... with 33 boys between the ages of 14 and 16, researchers ... for the closeness and trust. Very few boasted about sexual conquests ... with a girl. "In our culture, we have lots of ...
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
(Date:7/24/2014)... Drinking caffeine may worsen the hot flashes and night ... go through menopause, new survey data suggests. "While ... caffeine intake may be useful for those postmenopausal women ... researcher Dr. Stephanie Faubion, director of the Women,s Health ... But caffeine -- a stimulant found in coffee and ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2
... 24 UCI Medical Affiliates, Inc. (Other OTC: UCIA) announced ... Finance, Chief Financial Officer, and Secretary of UCI Medical Affiliates, ... federal court to criminal charges for falsifying eight of the ... On the eight reports that were submitted to the ...
... and phosphate content is common, but labeling is not ... -- Additives used to "enhance" uncooked meat and poultry ... disease, researchers say. , Many fresh meat and poultry ... and flavorings that are not required to be listed ...
... , , , ... ), a global leader in the field of radiosurgery, announced today ... Ill., has installed the CyberKnife((R)) Robotic Radiosurgery System in one of ... of this new CyberKnife configuration option, which can save hospitals both ...
... 24 Healthcare Informatics Associates (HIA), an InfoLogix company (Nasdaq: ... Hilo Medical Center (HMC) in Hilo, Hawaii for a multi-year engagement ... Region facilities. , , (Logo: ... , Hilo initially selected HIA among multiple competing vendors ...
... Sick people are being used as a "wedge" in a turf ... experts. , , Some hospitals ... hallways on unit floors, believing that will force nurses to find ... CEO and Vice President, respectively, at TeleTracking Technologies, leading maker of ...
... , , , ... hosted by the Kaiser Permanente Health Care Institute and the National ... for all Americans. Speakers discussed proven strategies for incentivizing coordinated care ... the way we cover health care, without actually reforming care delivery ...
Cached Medicine News:Health News:UCI Medical Affiliates, Inc.'s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges 2Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:First Customer Installs CyberKnife System in Existing Radiation Therapy Vault 2Health News:First Customer Installs CyberKnife System in Existing Radiation Therapy Vault 3Health News:First Customer Installs CyberKnife System in Existing Radiation Therapy Vault 4Health News:Healthcare Informatics Associates, an InfoLogix Company, Selected by Hilo Medical Center for MEDITECH 6.0 EMR Implementation 2Health News:Healthcare Informatics Associates, an InfoLogix Company, Selected by Hilo Medical Center for MEDITECH 6.0 EMR Implementation 3Health News:Are Patients Becoming Victims in Hospital Overcrowding Turf Wars? Experts Ask 2Health News:Teamwork, Technology, and Coordinated Care Improve Outcomes and Lower Costs 2Health News:Teamwork, Technology, and Coordinated Care Improve Outcomes and Lower Costs 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: